Company Filing History:
Years Active: 2014
Title: **The Ingenious Contributions of Krishnasamy Panneer-Selvam**
Introduction
Krishnasamy Panneer-Selvam, a talented inventor based in Poway, CA, is known for his inventive contributions in the field of biotechnology. His extensive research efforts culminated in one significant patent, which showcases his dedication to advancing medical science and treatment options.
Latest Patents
Panneer-Selvam holds a patent for "Glycopegylated Factor IX." This innovative invention provides conjugates between Factor IX and polyethylene glycol (PEG) moieties. The conjugates are linked through an intact glycosyl linking group that is covalently attached to both the peptide and the modifying group. The formation of these conjugates involves glycosylated peptides acted upon by glycosyltransferase, which ligates a modified sugar moiety to a glycosyl residue on the peptide. The patent also outlines methods for preparing these conjugates, treating various disease conditions, and developing pharmaceutical formulations that include these innovative compounds.
Career Highlights
Krishnasamy Panneer-Selvam is currently associated with Novo Nordisk A/S, a leading global healthcare company dedicated to innovative diabetes care and other critical health solutions. His work at Novo Nordisk has allowed him to contribute significantly to the biotechnology sector, enhancing treatments that improve patient outcomes.
Collaborations
During his career, Panneer-Selvam has collaborated with esteemed colleagues, including Shawn DeFrees and Robert J Bayer. These partnerships foster an environment of innovation, enabling the team to develop cutting-edge solutions in the field of healthcare.
Conclusion
Krishnasamy Panneer-Selvam stands out as a brilliant inventor whose work has the potential to transform medical treatments. His patent on glycopegylated Factor IX represents a significant step forward in biotechnology, indicative of his commitment to improving health outcomes through innovative solutions. As he continues his work at Novo Nordisk, the impact of his contributions will undoubtedly resonate within the field for years to come.